

FOSUN PHARMA  
复星医药

2023



1

2

3

4

5

6



2023

1/2







® PD-1

1H23 5.56

3 ES-SCLC

ES-SCLC

PD-1

3 ES-SCLC

MAA

EMA

9 ESCC



Argesun®



®

#

®

#



®

#



®

#



®



®



®



® HER2

RT002

#

Tenapanor

#

FS-1502 HER2-ADC #




13

FCN-159 MEK

ET-26



SAB Scientific Advisory Board








CDE 2021 7



DRG/DIP



药友制药 | FOSUN PHARMA  
 万邦医药 | FOSUN PHARMA  
 麒麟医药 | FOSUN PHARMA



Alma

FOSUN IDGENVAX  
复星安特金

cenexi  
 creating innovative partnerships  
 Gland Pharma  
 2023 4  
 CDMO Cenexi



mRNA



RT002

AMGEN® 安进

Parsabiv®



/ADC RNA




02




01

03












# MSCI-ESG A









-


1



2,3




3



# SCLC PD-1



PD-1



(ASTCT)

r/r LBCL

2023 6 r/r LBCL

CAR-T

B

LBCL  
1.3

LBCL NHL 45.8%

NHL

LBCL 4

ZUMA-1

RWS

ZUMA-7

bORR

bCR

OS

500

2023 6

140

25

10,000

GMP

2023 6

60

90

FL

MZL

2021 8

r/r FL

Kite Pharma

CAR-T  
/




B **Tecartus**

2020 7

FDA  
r/r ALL

/

MCL









-

1

1,2

1







1H23 /



BeautiFill  
LipoSense  
CellFie





1H23 34 330

1,100

2000 FDA 2023 6

8,042 55,000 1,000

**Ion**

2019 Ion  
FDA  
2021 10 Ion


Ion








1




2011-2017

2,3



2018-2020

3



2021

6,448 \* 9

JCI

1H23

" "



600

2017 11 9.09  
60%



1,750

2022

21.45

1.11

800

87.41%

900

2022 1

70%



\*

2023 6



406,382



3Q22

445,920





3Q23






5,857















2,254





		®		
		®		
		®		
		®		
		®*		

		®*		
		®*		
		®*		
	T	®*		
		®		
		®		

		®*		
		®*		
				
		®*		
		mRNA ®*		
				



# 1/2

			/		IND	1	2	3	NDA
HLX10 <sup>1</sup>	+	PD-1	/	III 2022 11					
				2022 11	2022	FDA/EC	2023 1		
	+ +	PD-1		III 2023 1	2022 5				
	+	PD-1+VEGF							
	+HLX07	PD-1+EGFR							
	+HLX07 +	PD-1+EGFR +VEGF		2022 1					
HLX07		EGFR							
HLX22									
HLX11	2	HER2							
HLX05	3	EGFR							
HLX02	4	HER2							
				FDA	2020				

1 KG Bio 10  
3  
5 2023 10 31

2 Organon  
4 Accord Cipla Jacobson mAbxience Eurofarma Abbott



			/		IND	1	2	3	NDA
	-	HER2	HER2	HER2					
		HER2+PD-1	HER2	HER2					

# 1/2

		/		IND	1	2	3	NDA
FCN-437c		CDK4/6	1L					
			2L					
SAF-189		ALK/ROS1	ALK+	2022 1 NMPA				III
			ROS1+					
HLX-208	-	BRAF	Erdheim-Chester LCH	2023 4 LCH ECD NMPA				
		BRAF+PD-1	BRAF V600E BRAF V600					
FCN-159		MEK	I	2023 7 NMPA				II
				2023 4 NMPA	2022 5 NMPA			
YP01001		VEGFR		NMPA				
FCN-338		BCL-2		NMPA				
			B					
FH-2001		FGFR/PD-L1						
ORIN1001		IRE1						

# 2/2

		/			IND	1	2	3	NDA
		TPO-R		ITP					
Tenapanor		NHE 3		(ESRD-HD)					
		P-CAB							
Tenapanor		NHE 3		(IBS-C)					
PA-824		-	XDR-TB /	MDR-TB					
Opicapone		COMT							
Fortacin		-							
ET-26		-			2023 10		III		
FCN-159		MEK							
ORIN1001		IRE1							
FCN-016		ROCK			2023 1	NMPA			
SZEY-2108		-		CRE	2023 6	NMPA			

			IND	1	2	3	NDA
	/						
	/						
	/						
13							
24							
23							
	-						

2023 10 31

LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and Fosun , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.



[www.fosunpharma.com](http://www.fosunpharma.com)